Bokku_niliya photo 1
bokku_niliya wallpaper

Did Kendall Jenner almost pull a John Travolta? The reality star fumbled over her words when introducing newcomers 5 Seconds of Summer at the Billboard Music Awards in Las Vegas. And now we welcome ... One ... the 21-year-old said seeming to almost say One Direction as she put her head down. Guys I am the worst reader. Jenner then introduced a video featuring the Australian pop group who performed their rising hit She Looks So Perfect. Other performers Sunday at the MGM Grand Garden Arena included Florida Georgia Line and Luke Bryan who were crowd favorites when they performed This Is How We Roll. Even Carrie Underwood and her hockey player-husband Mike Fisher sang along. Ariana Grande who turns 21 next month was semi-racy when she sang her hit Problem in a mini black and white dress alongside rapper Iggy Azalea. Grande was nominated for best new art but she lost to breakthrough New Zealander Lorde. Lorde entered the night as the top contender along with Imagine Dragons where the Billboard Music Awards marked a homecoming for Imagine Dragons. The Las Vegas-based rockers won the nights first trophy top rock album for their 2012 debut Night Visions at the awards show Sunday in Las Vegas. AQR sold AstraZeneca AQR Capital sold its position in AstraZeneca during the third quarter of 2014. The stock accounted for 0.24% of the 2Q14 portfolio. About AstraZeneca AstraZeneca is one of a few pure-play bio-pharmaceutical companies that span a medicine entire value chain. The company is involved in research early and late-stage development manufacturing and distribution. The company three important areas are: 1. Cardiovascular and metabolic disease 2. Oncology 3. Respiratory inflammation and autoimmunity AZN plans to expand its biologics-manufacturing center to support its maturing pipeline. Biologics currently represent ~50% of its overall pipeline. AstraZeneca to buy Definiens On November 4 AZN global biologics research and development arm agreed to acquire privately held Defines for $150 million. Defines has pioneered a world-leading imaging and data analysis technology which dramatically improves the identification of biomarkers in tumor tissue. The transaction will strengthen AZN focus in immuno-oncology. Slide in profit in 3Q14 Sales rose 5% to $6.54 billion helped by delays in the launch of a cheap copy of AstraZeneca heartburn pill Nexium by Ranbaxy Laboratories. Net profit fell to $254 million compared to $1.25 billion in 3Q13. Core earnings per share were $1.05 8% down from $1.22 as AZN is investing in marketing and new drug development. Its blood-thinning drug Brilinta reported revenue increase of 78%. The company diabetes franchise reported revenue growth of 139% due to the strong US Farxiga launch and good uptake of Bydureon Pen. Pipeline of products During the quarter FDA approved type 2 diabetes drug Xigduo XR and opioid-induced constipation treatment Movantik. AZN received a positive opinion by the Committee for Medicinal Products for Human Use (or CHMP) for Lynparza and ovarian cancer treatment. AstraZeneca achieved positive phase three data for intra-abdominal infection treatment with ceftazidime-avibactam and gout therapy with lesinurad. AstraZeneca divestment On November 6 AZN entered into a definitive agreement with Aegerion Pharmaceuticals Inc. (AEGR) to sell its Myalept drug for $325 million. Myalept treats a rare disease associated with the loss of fat tissue. With the divestment AZN can focus on core strategic priorities. Strategic transaction with Almirall On November 3 AZN completed a transaction with Almirall. AZN owns the rights to develop and commercialize Almirall proprietary respiratory business. This includes rights to revenues from Almirall existing partnerships. It also includes a pipeline of investigational novel therapies. Improved 2014 guidance Before AZN did not expect any growth for the year but now AZN expects sales to grow in low single digits for the full year. Previously the company expected a low double-digit decline but now it expects core earnings per share to decline by ~10%. AQR Capital other 3Q14 positions During 3Q14 AQR initiated a position in Bally Technologies. The firm increased its position in Gilead Sciences Inc. (GILD) Shire Plc (SHPG) Intel Corp (INTC) Glimcher Realty Trust (GRT) and Biogen Idec Inc. (BIIB). The firm also sold its position in Riverbed Technology Inc. (RVBD). The next part of this series will explore AQR position change in Riverbed Technology. Vaglio got steadily worse. After his daughter contacted ship personnel it took 20 minutes to get a wheelchair to take him from their cabin back to the infirmary. Then there was another delay while credit card information was obtained. Finally four hours after the accident and suffering from internal bleeding in his skull Vaglio was examined by the ship doctor and sent to a hospital in Bermuda. By that time Vaglio life was beyond saving the appeals judges wrote. He was airlifted to a hospital in Mineola New York where he died a week later. It is not clear whether the 11th Circuit will reconsider its ruling which conflicts with other circuits decisions and could ultimately wind up in the U.S. Supreme Court. Robert Peltz a veteran Miami maritime lawyer said if the decision stands the key for medical malpractice lawsuits to succeed will be proving the cruise lines control their medical staffs that they are not independent contractors. There is ample evidence of that control in the modern cruise industry. The Cruise Lines International Association for example requires members to have medical staff aboard all ships around the clock. The organization has developed guidelines and policies for cruise lines to maintain high-standard medical care said spokeswoman Elinore Boeke. Cruise ships go to great lengths to keep passengers healthy and well she said. Still Royal Caribbean said it is unfair for purposes of a lawsuit to compare cruise ships to an onshore medical center with numerous specialists and access to lab work and test equipment. Cruise ships are still not floating hospitals their lawyers wrote. For now the 11th Circuit ruling would merely give Pasquale Vaglio relatives a chance to prove their claims that the Explorer of the Seas medical staff was negligent in his August 2011 death. Unless Royal Caribbean offers a settlement the Vaglios will have to convince a Miami jury they deserve damages but Joseph Vaglio said money is not the only motivation. They were getting away with this for a long time and it is time for it to stop he said. My dad was the nicest guy in the world. When he left early it was kind of weird. It took a lot of years away from me.